Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MT 2271

Next Previous
Drug Profile

MT 2271

Alternative Names: Influenza virus vaccine quadrivalent - Tanabe Pharma Corporation; MT-2271; Quadrivalent seasonal influenza VLP vaccine - Medicago; Seasonal influenza vaccine quadrivalent - Medicago; Seasonal influenza virus-like particle (VLP) vaccine - Medicago

Latest Information Update: 11 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medicago
  • Developer Medicago; Mitsubishi Tanabe Pharma Corporation
  • Class Influenza virus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Influenza virus infections

Most Recent Events

  • 01 Dec 2025 Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation
  • 22 Oct 2021 Discontinued - Phase-III for Influenza virus infections (In the elderly, Prevention) in Finland and Germany (IM) (Mitsubishi Tanabe Pharmaceutical's pipeline, October 2021)
  • 22 Oct 2021 Discontinued - Phase-III for Influenza virus infections (Prevention, In adults) in Finland and Germany (IM) (Mitsubishi Tanabe Pharmaceutical's pipeline, October 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top